MDA DMD에 흉터, 염증 완화 약물의 자금 지원

HT-100 전투 염증과 근육의 반흔 조직 형성, 둘 다 근육 재생을 방해하고 치료에 장벽 및 건강한 근육 섬유의 재생을 촉진 할 수 있습니다.
HT-100는 현재 Duchenne의 MD 30명의 소년과 젊은 남성의 다섯을 현장 임상 연구에서 평가하고 있습니다.
HT-100의 개발 자금을 돕는 MDA 벤처 자선 (MVP) 프로그램은, 실험실 및 임상 시험에 유망한 화합물을 이동하도록 설계되어 있습니다.

HT-100 약물의 자금지원 뉴스입니다.

원문 나갑니다.

MDA has awarded a grant of $500,000 to Newton, Mass., biopharmaceutical company Halo Therapeutics for development of HT-100, an experimental drug for Duchenne muscular dystrophy (DMD).

HT-100, now in a 30-person clinical trial in boys and young men with DMD, is an oral compound designed to reduce damaging inflammation and fibrosis (scar tissue formation) in DMD-affected muscles, and to promote regeneration of healthy muscle fibers. The study is being conducted at five leading academic research sites across the U.S. Recruitment for this trial is complete.

The award, which will run through Nov. 15, 2014, was made through MDA Venture Philanthropy (MVP), the drug development arm of the organization’s program in translational research. The goal of translational research is the movement of promising therapeutic compounds from the laboratory to the clinic.

"Excessive inflammation and fibrosis in muscle can interfere with muscle regeneration and can be a significant barrier to certain therapies now in development, such as gene replacement," said Jane Larkindale, MDA's vice president of research. "Drugs like HT-100 have the potential to be used on their own or in conjunction with other treatments. A rigorous review process conducted by MVP has determined that Halo has the capability of taking HT-100 forward in an efficient and safe manner."

출처:http://quest.mda.org/news/mda-funds-development-drug-fight-inflammation-scarring-dmd